CARLSBAD, Calif., May 30, 2023 — Deal Box, a capital markets advisory and secure token offering packaging platform, today revealed that Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a leading pharmaceutical, biotechnology, and MedTech company focused on creating cost-effective treatments for people with chronic illnesses, will be utilizing Deal Box’s capital raising technology and Investment Packaging (TM) formula to raise USD 12 million. Biostax will be able to accelerate expansion and innovation thanks to Deal Box’s capital funding strategy, as well as extend its reach to markets with a high prevalence of health issues and increased healthcare costs.
By 2030, with a growth rate of 10.8%, the worldwide healthcare and life sciences business is anticipated to reach $330.69 billion. The COVID-19 pandemic is a significant factor in the industry’s explosive expansion, and it will continue to require the support of businesses like Biostax.
Biostax promotes developing and commercializing proprietary methods, such as pharmaceutical, biotechnology, and MedTech solutions, to prevent, intercept, and treat autoimmune and chronic disorders to enhance healthcare outcomes. Ideally, The company’s goal aligns with Deal Box’s commitment to funding forward-thinking businesses that want to make the world a better place.
According to Thomas Carter, CEO and Chairman of Deal Box, “Biostax brings cutting-edge technology and a dedication to growth to the table, as well as, aiming to provide medical care to those with little access, which will undoubtedly bring forth immense value to investors.” “We are thrilled to support Biostax through this growth capital round. They are fixated on redefining what accessible health care means to society.”
“We are excited to begin our growth investment round and even more excited to have Deal Box on board with us. Deal Box is dedicated to helping our firm through a period of rapid growth and expansion into a market with enormous potential and to being just as committed to our purpose as we are, according to Kelly Wilson, CEO of Biostax. The Deal Box platform is straightforward and practical, saving us time with irrelevant investors and guiding us to raise more money from important investors that value our aim to reimagine access to affordable healthcare.
The innovative pharmaceutical business Biostax Corp. specialises in purchasing, developing, and commercializing pharmaceutical and biotechnology products with a clear road to market. The company intends to advance focused and effective small-scale biotechnology and pharmaceutical programmes through subsidiaries, investment vehicles, or partnerships and deploy its products from those programmes in markets both in the U.S. and abroad for initial commercialization. This will be accomplished by using a biotech portfolio hub-and-spoke engine.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 ("Biostax"), a leading pharmaceutical, biotechnology, and MedTech company focused on creating cost-effective treatments for people with chronic illnesses, will be utilizing Deal Box's capital raising technology and Investment Packaging (TM) formula to raise USD 12 million. Biostax will be able to accelerate expansion and innovation thanks to Deal Box's capital funding strategy, as well as extend its reach to markets with a high prevalence of health issues and increased healthcare costs.){kind=link}